Summary by Moomoo AI
RedHill Biopharma Ltd., an Israeli biopharmaceutical company, filed a Post-Effective Amendment No. 1 to Form F-1 with the SEC on April 18, 2024. This amendment pertains to the registration of 10,600,000 American Depositary Shares (ADSs), representing 4,240,000,000 ordinary shares. The ADSs are issuable upon the exercise of previously issued warrants as part of a concurrent private placement during a registered direct offering in January 2024. The warrants, exercisable immediately upon issuance at a price of $1.00 per ADS, will expire five years from the date of issuance. The registration statement was initially filed on February 9, 2024, and declared effective by the SEC on February 15, 2024. The amendment includes the incorporation of the company's Form 20-F for the year ended December 31, 2023, filed on April 8, 2024, and updates selling shareholder...Show More